nitrofurantoin has been researched along with allopurinol in 23 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 5 (21.74) | 18.7374 |
1990's | 1 (4.35) | 18.2507 |
2000's | 7 (30.43) | 29.6817 |
2010's | 10 (43.48) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Duffy, EM; Jorgensen, WL | 1 |
Topliss, JG; Yoshida, F | 1 |
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
Lombardo, F; Obach, RS; Waters, NJ | 1 |
González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
Ekins, S; Williams, AJ; Xu, JJ | 1 |
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
Shen, RS; Zhang, YX | 1 |
Boyd, MR; Ho, PC; Minchin, RF | 1 |
Behrens, BC; Bryan, GT; Ichikawa, M; Wang, CY | 1 |
Elstner, EF; Osswald, WF; Youngman, RJ | 2 |
Wright, R | 1 |
Ben Sghaier, M; Bhouri, W; Boubaker, J; Bouhlel, I; Chekir-Ghedira, L; Ghedira, K; Kilani, S; Neffati, A; Skandrani, I | 1 |
2 review(s) available for nitrofurantoin and allopurinol
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Drug-induced chronic hepatitis.
Topics: Allopurinol; Chemical and Drug Induced Liver Injury; Cholestasis; Chronic Disease; Female; Granuloma; Hepatitis; Humans; Indoles; Liver Cirrhosis; Methyldopa; Nitrofurantoin; Oxyphenisatin Acetate; Phenylbutazone | 1980 |
21 other study(ies) available for nitrofurantoin and allopurinol
Article | Year |
---|---|
Prediction of drug solubility from Monte Carlo simulations.
Topics: Monte Carlo Method; Pharmaceutical Preparations; Solubility | 2000 |
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
Antioxidation activity of tetrahydrobiopterin in pheochromocytoma PC 12 cells.
Topics: Adrenal Gland Neoplasms; Animals; Antioxidants; Biopterins; Dihydropteridine Reductase; NAD; Nitrofurantoin; Peroxidases; Pheochromocytoma; Rats; Tumor Cells, Cultured; Xanthine Oxidase | 1991 |
Reductive metabolism of nitrofurantoin by rat lung and liver in vitro.
Topics: Allopurinol; Animals; Chromatography, High Pressure Liquid; In Vitro Techniques; Kinetics; Liver; Lung; Male; Nitrofurantoin; Oxidation-Reduction; Rats; Rats, Inbred Strains; Superoxides; Vitamin K | 1986 |
Nitroreduction of 5-nitrofuran derivatives by rat liver xanthine oxidase and reduced nicotinamide adenine dinucleotide phosphate-cytochrome c reductase.
Topics: Acetamides; Allylisopropylacetamide; Animals; Carbon Radioisotopes; Chromatography, Ion Exchange; Cytochrome c Group; Cytochrome Reductases; Cytosol; Dialysis; Electron Transport; Female; Hydrazines; In Vitro Techniques; Liver; Methylcholanthrene; Microsomes, Liver; Milk; NADP; Nitrofurans; Nitrofurantoin; Oxidation-Reduction; Phenobarbital; Protein Binding; Rats; Thiazoles; Xanthine Oxidase | 1974 |
Mechanisms of oxygen activation by nitrofurantoin and relevance to its toxicity.
Topics: Catalase; Ethylenes; Euglena gracilis; Free Radicals; NADP; Nitrofurantoin; Oxygen; Superoxide Dismutase; Superoxides; Xanthine Oxidase | 1982 |
Crypto - OH. radical production by nitrofurantoin.
Topics: Chemical Phenomena; Chemistry; Ethylenes; Free Radicals; NADPH-Ferrihemoprotein Reductase; Nitrofurantoin; Oxidation-Reduction; Xanthine Oxidase | 1982 |
Chemical investigation of different crude extracts from Teucrium ramosissimum leaves. Correlation with their antigenotoxic and antioxidant properties.
Topics: Aflatoxin B1; Antimutagenic Agents; Antioxidants; Escherichia coli; Mutagens; Nitrofurantoin; Plant Extracts; Plant Leaves; SOS Response, Genetics; Teucrium; Xanthine Oxidase | 2011 |